XTL Biopharmaceuticals is developing HepeX-C, a combination of two antibodies (HCV-AB68 and HCV-AB65) as a potential therapy for hepatitis C virus infection. By September 2003, phase II trials of HCV-AB68 alone had been conducted and XTL Biopharmaceuticals announced that it planned to conduct a phase I study of the antibody combination.
HepeX-C (XTL Biopharmaceuticals) / Borgia, Guglielmo. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - ELETTRONICO. - 5:(2004), pp. 892-897.
HepeX-C (XTL Biopharmaceuticals).
BORGIA, GUGLIELMO
2004
Abstract
XTL Biopharmaceuticals is developing HepeX-C, a combination of two antibodies (HCV-AB68 and HCV-AB65) as a potential therapy for hepatitis C virus infection. By September 2003, phase II trials of HCV-AB68 alone had been conducted and XTL Biopharmaceuticals announced that it planned to conduct a phase I study of the antibody combination.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
